Surprisingly, NU7441, a selective inhibitor of DNA-PKcs [23], was identified as one of the two lead therapies, as NU7441 could alter a variety of immunomodulatory proteins, e.g., CD55, CD73, CD155, programmed death-ligand 1 (PD-L1), nerve growth factor receptor (NGFR), and HLA (human leukocyte antigen) class I in a heterogeneous panel of melanomas, leading to proliferative inhibition of melanoma cells [19]. Here, PRKDC is linked to melanoma.